关键词：视网膜母细胞瘤；儿童；儿童癌症病例；遗传性疾病
摘 要：Retinoblastoma is rare eye cancer that occurs predominantly in children younger than 15 years old. It accounts for nearly 3% of pediatric cancer cases worldwide. It is a genetic disorder that originates in the retina and slowly progresses toward the outer part of the eye. The growth of the tumor can be endophytic, exophytic, or diffuse infiltrating. In the endophytic pattern, the tumor grows into the vitreous cavity; however, the retinal blood vessels are not visible on the surface of the tumor. In the exophytic pattern, the tumor grows close to the subretinal space; the presence of retinal blood vessels in the tumor surface is also observed. The diffuse pattern of tumor growth is usually seen in older children, as it makes the retina thick and causes delayed diagnosis.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Retinoblastoma overview

Understanding retinoblastoma

Etiology

Classification

Symptoms

Diagnosis

Patient examination

Imaging tests

Biopsy tests

Clinical tests

Epidemiology

Staging

Management

Cryotherapy

Chemotherapy

Photocoagulation

Radiation therapy

Surgery

Thermotherapy

PART 06: Market landscape

Market overview

Five forces analysis

PART 07: Pipeline Analysis

Key information of pipeline candidates

PART 08: Market segmentation by therapeutic class of

drugs

Alkylating agents

Antimetabolites

Microtubule inhibitors

Cytotoxic antibiotics

Topoisomerase inhibitors

Others

PART 09: Market segmentation by disease status

Unilateral retinoblastoma

Bilateral retinoblastoma

PART 10: Geographical segmentation

PART 11: Market growth drivers

Increase in public awareness

Increase in incidence of the disease

Provision for rare diseases

Development of targeted therapies

PART 12: Impact of drivers

PART 13: Market challenges

Treatment abandonment

Limited healthcare access

Alternative treatment options

PART 14: Impact of drivers and challenges

PART 15: Market trends

Localized treatment approach

Twinning programs

Improving survival rate

PART 16: Vendor landscape

Competitive scenario

Market share analysis 2014

Other prominent vendors

PART 17: Key Vendor Analysis

Baxter International Inc.

Bristol-Myers Squibb

GlaxoSmithKline

Spectrum Pharmaceuticals

PART 18: Appendix

List of abbreviations

PART 19: Explore Technavio